The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation
Hyperpigmentation, Post-inflammatory Hyperpigmentation, Acne
About this trial
This is an interventional treatment trial for Hyperpigmentation
Eligibility Criteria
Inclusion Criteria: Males and females between the ages of 14 years of age until 55 years of age Individuals experiencing 3 different areas minimum of facial post-inflammatory hyperpigmentation in those with acne Exclusion Criteria: Individuals who are pregnant or breastfeeding. Prisoners. Adults unable to consent. Those who are unwilling to discontinue hydroquinone, vitamin A/C/E, azelaic acid, kojic acid, bakuchiol, licorice root, retinol, niacinamide, alpha arbutin, and oral or topical tranexamic acid for two weeks to meet the washout criteria prior to enrolling and for the duration of the study. Subjects with any of the following facial cosmetic treatments within the past 3 months or those who are unwilling to withhold the following facial cosmetic treatments during study including microdermabrasion, intense pulsed light (IPL), peels, laser treatments, acid treatments, or any other medical treatment administered by a physician or skin care professional which is designed to improve skin pigmentation. Individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study. Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years.
Sites / Locations
Arms of the Study
Arm 1
Experimental
Topical Cetyl Tranexamate Mesylate
Product will be used on the face twice daily in the morning and in the evening for 2 weeks.